Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Appili Therapeutics Inc. (T:APLI)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for APLI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 12, 2024 07:12 ET
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in...
Read full article
Feb 13, 2024 17:49 ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.11
--
--
Price to Sales - TTM
3.16
6.34
3.46
Price to Book - most recent quarter
--
1.83
2.02
Price to Cash Flow per share - TTM
--
3.87
9.70
Price to Free Cash Flow per share - TTM
--
18.65
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 202432,882-1,313
Feb 29, 202434,1951,060
Feb 15, 202433,135326
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company's anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

See business summary

 

Twitter

Search (past week) for $APLI.CA

  • No tweets found